ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 9.93B 8.51B 7.96B 7.28B 13.73B 951B 13.88B 94.18B 36.62B 477B 37.28B 36.47B 1,579B | P/E 2026 * |
-16.4x | P/E 2027 * | -31.6x |
|---|---|---|---|---|---|
| Enterprise Value | 9.82B 8.42B 7.88B 7.2B 13.59B 941B 13.73B 93.21B 36.24B 472B 36.89B 36.09B 1,563B | EV / Sales 2026 * |
10.8x | EV / Sales 2027 * | 7.12x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 9.93B | |
| -0.74% | +3.78% | +2.62% | +23.10% | 51.61B | |
| +0.97% | -0.49% | +491.42% | +562.98% | 44.89B | |
| -0.06% | +7.56% | +38.00% | +20.40% | 42.77B | |
| -0.89% | +2.37% | +20.24% | +86.59% | 42.58B | |
| +0.88% | -3.48% | +17.20% | +57.20% | 31.82B | |
| -0.52% | +3.34% | +32.18% | +144.06% | 17.33B | |
| -0.56% | +1.58% | - | - | 16.63B | |
| +0.58% | +4.66% | +9.77% | +30.87% | 14.76B | |
| +0.01% | +2.86% | +79.67% | +48.45% | 14.09B | |
| Average | +0.05% | +4.83% | +86.39% | +121.71% | 30.72B | |
| Weighted average by Cap. | -0.10% | +5.13% | +104.13% | +140.40% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 913M 783M 732M 670M 1.26B 87.46B 1.28B 8.67B 3.37B 43.92B 3.43B 3.36B 145B | 1.4B 1.2B 1.12B 1.03B 1.94B 134B 1.96B 13.3B 5.17B 67.42B 5.26B 5.15B 223B |
| Net income | -602M -516M -483M -442M -833M -57.68B -842M -5.72B -2.22B -28.97B -2.26B -2.21B -95.84B | -326M -279M -261M -239M -451M -31.2B -456M -3.09B -1.2B -15.67B -1.22B -1.2B -51.84B |
| Net Debt | -103M -88.24M -82.55M -75.47M -142M -9.86B -144M -977M -380M -4.95B -387M -378M -16.38B | 57.45M 49.24M 46.06M 42.11M 79.47M 5.5B 80.32M 545M 212M 2.76B 216M 211M 9.14B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
